Melanoma cells with the constitutive activation of downstream signaling pathways due to oncogene mutations (e.g., K-Ras or B-Raf) or the loss of tumor suppressor genes (e.g., PTEN) may not respond as effectively to cetuximab treatments [24]. This evidence concerns the gene BRAF and neoplasm.